SARS-CoV-2 Is a Robot Bioweapon

2022 ◽  
pp. 114-164
Author(s):  
Li-Meng Yan ◽  
Adrian David Cheok
Keyword(s):  
Synthetic Route ◽  
Natural Evolution ◽  
Natural Origin

Two possibilities should be considered for the origin of SARS-CoV-2: natural evolution or laboratory creation. In the authors' earlier report titled “Unusual Features of the SARS-CoV-2 Genome Suggesting Sophisticated Laboratory Modification Rather Than Natural Evolution and Delineation of Its Probable Synthetic Route,” they disproved the possibility of SARS-CoV-2 arising naturally through evolution and instead proved that SARS-CoV-2 must have been a product of laboratory modification. Despite this and similar efforts, the laboratory creation theory continues to be downplayed or even diminished. This is fundamentally because the natural origin theory remains supported by several novel coronaviruses published after the start of the outbreak. Here, however, the authors use in-depth analyses of the available data and literature to prove that these novel animal coronaviruses do not exist in nature.

The Anticoagulant Effect of Heparinoid Org 10172 During Haemodialysis: An Objective Assessment

1986 ◽  
Vol 55 (02) ◽  
pp. 271-275 ◽  
Author(s):  
Helen Ireland ◽  
D A Lane ◽  
Angela Flynn ◽  
E Anastassiades ◽  
J R Curtis
Keyword(s):  
Renal Failure ◽  
Bolus Dose ◽  
Bolus Injection ◽  
Objective Assessment ◽  
Factor Xa ◽  
Fibrin Clot ◽  
Natural Origin ◽  
Fibrin Formation ◽  
Single Bolus Injection

SummaryThe heparinoid of natural origin Org 10172 has anti-factor Xa activity but minimal anti-thrombin activity, and little effect upon broad spectrum assays such as the KCCT in vitro. Its anticoagulant effects have been compared to those of commercial heparin in 7 patients undergoing haemodialysis for chronic renal failure. Commercial heparin was administered in a dose (5,000 iu bolus + 1,500 iu/hour continuous iv infusion) previously shown to inhibit fibrin formation during haemodialysis. This produced mean anti-factor Xa levels in plasma between 0.7-1.0 iu/ml and largely suppressed fibrin formation for 5 h dialysis measured as mean FPA levels in plasma. Administration of Org 10172 as a bolus of 1,350 anti-factor Xa u or 2,000-2,400 anti-factor Xa u produced plasma anti-factor Xa levels of less than 0.5 u/ml and allowed fibrin clot and FPA generation during dialysis. Org 10172 administered as a bolus dose of 4,000-4,800 anti-factor Xa u produced mean anti-factor Xa levels of greater than 0.5 u/ml, allowed dialysis of 6 patients for 5 h and appreciably suppressed FPA generation during dialysis, with little effect on the KCCT.It is concluded that the anti-factor Xa activity of Org 10172 may reflect its ability to inhibit fibrin during dialysis and that single bolus injection of Org 10172 may be a useful alternative method of achieving anticoagulation.

A General Convergent Strategy for the Synthesis of Tetrasubstituted Furan Fatty Acids (FuFAs)

2019 ◽  
Author(s):  
Yamin Wang ◽  
Gareth Pritchard ◽  
Marc Kimber
Keyword(s):  
Fatty Acids ◽  
Spectral Data ◽  
Synthetic Route ◽  
Furan Fatty Acids

Synthetic route for the synthesis of tetrasubstituted furan fatty acids; including experimental details, characterisation, and spectral data of all intermediates.

Palladium-Catalyzed Asymmetric Annulation Between Aryl Iodides and Racemic Epoxides Using a Chiral Norbornene Cocatalyst

2018 ◽  
Author(s):  
Guangbin Dong ◽  
Renhe Li
Keyword(s):  
Isopropyl Ester ◽  
Synthetic Route ◽  
Initial Development ◽  
Aryl Iodides ◽  
Palladium Catalyzed

Herein, we describe our initial development of an asymmetric Pd-catalyzed annulation between aryl iodides and racemic epoxides for synthesis of 2,3-dihydrobenzofurans using a chiral norbornene cocatalyst. A series of enantiopure ester-, amide- and imide-substituted norbornenes have been prepared with a reliable synthetic route. Promising enantioselectivity (42-45% ee) has been observed using the isopropyl ester-substituted norbornene (N1*) and the amide-substituted norbornene (N7*).

Determination of the prevalence of helicobacter pylori oral infection in smoking patients with chronic generalized periodontitis on the background of chronic hyperacidal gastritis during treatment

2020 ◽  
Vol 40 (4) ◽  
pp. 50-54
Author(s):  
O. L. Zolotukhina ◽  
◽  
Ju. G. Romanova ◽  
O. V. Maslov ◽  
◽  
...  
Keyword(s):  
Risk Factors ◽  
Helicobacter Pylori ◽  
Oral Cavity ◽  
Urease Activity ◽  
Rapid Test ◽  
Oral Infection ◽  
Helicobacter Pylori Infection ◽  
Natural Origin ◽  
Periodontal Tissues

Diseases of periodontal tissues occupy one of the leading positions among modern dental problems, namely the multifactorial nature of these diseases. In modern dental science, the issue of the development of periodontal pathology against the background of somatic pathology and risk factors remains relevant. Pathology of periodontal tissues in 68–90 % of cases is accompanied by chronic diseases of the gastrointestinal tract. Today, there is no doubt that Helicobacter pylori infection can be present in the biotopes of the oral cavity and can affect the course of periodontal pathology. As you know, smoking is one of the important risk factors for the development of inflammatory-dystrophic diseases of periodontal tissues, which can aggravate the course of the latter. The purpose of the work is to determine the prevalence of oral Helicobacter pylori infection in tobacco-dependent patients with chronic generalized periodontitis on the background of chronic hyperacid gastritis during treatment. Patients who received the proposed therapeutic and prophylactic complex (ultraphonophoresis procedures with the created gel «Apisan», and probiotic drug BioGaia ProDentis and angioprotective drug of natural origin — Detralex) showed a gradual decrease in the level of total urease activity and, as a consequence, a decrease the prevalence of Helicobacter pylori infection in the oral cavity according to the results of a urease rapid test with material from the oral cavity, both in the presence of a risk factor — smoking, and in its absence. The use of the proposed therapeutic and prophylactic complex proved to be effective in reducing the prevalence of oral Helicobacter pylori infection in smoking patients and patients who do not smoke, with chronic generalized periodontitis against the background of chronic hyperacidal gastritis associated with Helicobacter pylori.

Sign in / Sign up

Export Citation Format

Share Document